La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Ono Pharmaceutical Croissance future

Future contrôle des critères 0/6

Les bénéfices de Ono Pharmaceutical devraient diminuer de 10.2% par an tandis que son chiffre d'affaires annuel devrait croître de 0.5% par an. Le BPA devrait croître de diminuer de 9.7% par an. Le rendement des capitaux propres devrait être 8.2% dans 3 ans.

Informations clés

-10.2%

Taux de croissance des bénéfices

-9.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	13.9%
Taux de croissance des recettes	0.5%
Rendement futur des capitaux propres	8.2%
Couverture par les analystes	Good
Dernière mise à jour	19 Aug 2024

Mises à jour récentes de la croissance future

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 04

Recent updates

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 04

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Jun 24

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Mar 04

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Feb 27

Prévisions de croissance des bénéfices et des revenus

TSE:4528 - Estimations futures des analystes et données financières antérieures (JPY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2027	515,323	78,336	75,181	117,258	9
3/31/2026	511,067	77,314	62,440	104,903	10
3/31/2025	480,277	74,367	-135,369	27,300	10
6/30/2024	500,331	120,953	105,249	121,111	N/A
3/31/2024	502,672	127,977	89,831	110,660	N/A
12/31/2023	498,070	127,611	91,301	106,044	N/A
9/30/2023	489,199	124,875	97,371	115,354	N/A
6/30/2023	460,481	115,064	98,429	116,894	N/A
3/31/2023	447,187	112,723	145,113	159,610	N/A
12/31/2022	428,951	111,555	137,391	149,495	N/A
9/30/2022	403,985	96,568	93,387	102,437	N/A
6/30/2022	380,720	85,922	78,395	88,151	N/A
3/31/2022	361,361	80,519	49,552	61,829	N/A
12/31/2021	345,781	73,558	38,233	53,343	N/A
9/30/2021	332,887	81,866	60,412	83,032	N/A
6/30/2021	321,734	78,003	47,401	70,321	N/A
3/31/2021	309,284	75,425	53,684	73,977	N/A
12/31/2020	302,054	74,364	53,088	72,011	N/A
9/30/2020	293,886	66,737	55,742	70,596	N/A
6/30/2020	293,351	64,870	58,824	78,232	N/A
3/31/2020	292,420	59,704	51,712	74,157	N/A
12/31/2019	290,736	60,233	43,202	73,947	N/A
9/30/2019	293,247	55,510	38,797	66,058	N/A
6/30/2019	291,374	52,633	32,152	58,850	N/A
3/31/2019	288,634	51,539	37,172	66,774	N/A
12/31/2018	284,463	51,978	42,500	67,269	N/A
9/30/2018	284,785	57,919	29,645	61,700	N/A
6/30/2018	272,165	53,746	16,591	48,716	N/A
3/31/2018	261,836	50,284	N/A	15,727	N/A
12/31/2017	256,522	54,760	N/A	28,754	N/A
9/30/2017	248,517	53,884	N/A	40,205	N/A
6/30/2017	246,953	53,887	N/A	53,650	N/A
3/31/2017	244,797	55,793	N/A	74,450	N/A
12/31/2016	236,710	48,270	N/A	44,743	N/A
9/30/2016	207,707	36,225	N/A	32,972	N/A
6/30/2016	183,345	29,206	N/A	16,805	N/A
3/31/2016	160,284	24,979	N/A	12,842	N/A
12/31/2015	140,927	16,449	N/A	29,716	N/A
9/30/2015	143,697	21,568	N/A	31,169	N/A
6/30/2015	139,663	19,521	N/A	30,488	N/A
3/31/2015	135,775	12,976	N/A	31,579	N/A
12/31/2014	137,592	17,663	N/A	N/A	N/A
9/30/2014	133,926	13,474	N/A	19,681	N/A
6/30/2014	137,146	16,787	N/A	N/A	N/A
3/31/2014	143,247	20,350	N/A	28,422	N/A
12/31/2013	145,946	21,574	N/A	N/A	N/A
9/30/2013	145,984	23,205	N/A	18,773	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Les bénéfices de 4528 devraient diminuer au cours des 3 prochaines années ( -10.2% par an).

Bénéfices vs marché: Les bénéfices de 4528 devraient diminuer au cours des 3 prochaines années ( -10.2% par an).

Croissance élevée des bénéfices: Les bénéfices de 4528 devraient baisser au cours des trois prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 4528 ( 0.5% par an) devrait croître plus lentement que le marché de JP ( 4.3% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 4528 ( 0.5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 4528 devrait être faible dans 3 ans ( 8.2 %).

Ono Pharmaceutical Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Consensus EPS estimates fall by 23%

Price target decreased by 10% to JP¥2,336

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Price target increased by 7.4% to JP¥2,935

Recent updates

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Final dividend of JP¥40.00 announced

Consensus EPS estimates fall by 23%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Price target decreased by 10% to JP¥2,336

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Price target increased by 7.4% to JP¥2,935

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥40.00 per share at 2.8% yield

Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.

Now 20% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥33.00 per share at 2.4% yield

Price target decreased by 7.4% to JP¥3,292

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥33.00 per share

Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued

Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Full year 2022 earnings: EPS misses analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Consensus EPS estimates fall by 11%

Now 21% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥28.00 per share

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 11,000,000 shares, representing 2.2% for ¥30,000 million.

Second quarter 2022 earnings released: EPS JP¥44.51 (vs JP¥36.77 in 2Q 2021)

Upcoming dividend of JP¥28.00 per share

Exelixis, Inc. Announces Partner Takeda Pharmaceutical Company Limited and Ono Receive Approval in Japan for CABOMETYX in Combination with Opdivo for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

First quarter 2022 earnings released: EPS JP¥48.23 (vs JP¥43.07 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Upcoming dividend of JP¥22.50 per share

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

New 90-day low: JP¥3,020

Third quarter 2021 earnings released: EPS JP¥53.37 (vs JP¥38.09 in 3Q 2020)

Revenue and earnings beat expectations

ONO Receives a Manufacturing and Marketing Approval of Adlumiz (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan

Ono Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 01, 2021